Next-generation anti-VEGF agents for diabetic macular oedema

Matias Iglicki*, David Pérez González, Anat Loewenstein, Dinah Zur

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.

Original languageEnglish
Pages (from-to)273-277
Number of pages5
JournalEye
Volume36
Issue number2
DOIs
StatePublished - Feb 2022

Fingerprint

Dive into the research topics of 'Next-generation anti-VEGF agents for diabetic macular oedema'. Together they form a unique fingerprint.

Cite this